These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33706100)

  • 1. PARP inhibition suppresses topoisomerase 1 poisoning induced Caspase-3 dependent cell death in zebrafish embryos.
    Tsikarishvili S; Karapetian M; Kulikova N; Zaalishvili G
    Biochem Biophys Res Commun; 2021 Apr; 550():166-170. PubMed ID: 33706100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
    Karapetian M; Tsikarishvili S; Kulikova N; Kurdadze A; Zaalishvili G
    DNA Repair (Amst); 2020 Mar; 87():102772. PubMed ID: 31877465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
    Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
    Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
    Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
    Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
    Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV
    Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
    Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
    Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells.
    Xiao LY; Kan WM
    Anticancer Drugs; 2017 Mar; 28(3):316-321. PubMed ID: 28207569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
    Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
    Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
    Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
    Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.
    Park SY; Cheng YC
    Cancer Res; 2005 May; 65(9):3894-902. PubMed ID: 15867389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin.
    Park SY; Leung CH; Cheng YC
    Mol Pharmacol; 2008 Jun; 73(6):1829-37. PubMed ID: 18349103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
    Znojek P; Willmore E; Curtin NJ
    Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.